RT Journal Article
T1 Predicting Circulating CA125 Levels among Healthy Premenopausal Women.
A1 Sasamoto, Naoko
A1 Babic, Ana
A1 Rosner, Bernard A
A1 Fortner, Renée T
A1 Vitonis, Allison F
A1 Yamamoto, Hidemi
A1 Fichorova, Raina N
A1 Tjønneland, Anne
A1 Hansen, Louise
A1 Overvad, Kim
A1 Kvaskoff, Marina
A1 Fournier, Agnès
A1 Romana Mancini, Francesca
A1 Boeing, Heiner
A1 Trichopoulou, Antonia
A1 Peppa, Eleni
A1 Karakatsani, Anna
A1 Palli, Domenico
A1 Pala, Valeria
A1 Mattiello, Amalia
A1 Tumino, Rosario
A1 Grasso, Chiara C
A1 Onland-Moret, N Charlotte
A1 Weiderpass, Elisabete
A1 Quirós, J Ramón
A1 Lujan-Barroso, Leila
A1 Rodriguez-Barranco, Miguel
A1 Colorado-Yohar, Sandra
A1 Barricarte, Aurelio
A1 Dorronsoro, Miren
A1 Idahl, Annika
A1 Lundin, Eva
A1 Sartor, Hanna
A1 Khaw, Kay-Tee
A1 Key, Timothy J
A1 Muller, David
A1 Riboli, Elio
A1 Gunter, Marc J
A1 Dossus, Laure
A1 Kaaks, Rudolf
A1 Cramer, Daniel W
A1 Tworoger, Shelley S
A1 Terry, Kathryn L
AB Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥35 U/mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC). The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC (r = 0.22) and in EPIC (r = 0.22). The dichotomous CA125 prediction model included age, tubal ligation, endometriosis, prior personal cancer diagnosis, family history of ovarian cancer, number of miscarriages, menstrual phase at blood draw, and smoking status with AUC of 0.83. The abridged dichotomous model (including age, number of miscarriages, menstrual phase at blood draw, and smoking status) showed similar AUCs in NEC (0.73) and in EPIC (0.78). We identified a combination of factors associated with CA125 levels in premenopausal women. Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.
PB American Association for Cancer Research
YR 2019
FD 2019-04-04
LK http://hdl.handle.net/10668/13790
UL http://hdl.handle.net/10668/13790
LA en
NO Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, et al.  Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1076-1085.
DS RISalud
RD Apr 7, 2025